Positive pivotal top-line data demonstrates 20-valent pneumococcal conjugate vaccine candidate (20vPnC), if approved, can likely help protect against all 20 vaccine serotypes in three-dose series
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the
NEW YORK CITY (dpa-AFX) - Drug major Pfizer Inc. (PFE) announced Friday positive top-line results from its pivotal U.S. Phase 3 study (NCT04382326) evaluating its 20-valent pneumococcal conjugate
France: Implementing a 13-valent pneumococcal conjugate vaccine (PCV13) in the general pediatric population may reduce the incidence of acute chest syndrome (ACS) in children with sickle-cell disease.
KENILWORTH (NJ) (dpa-AFX) - The U.S. Food and Drug Administration has approved an expanded indication for Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) to include children 6 weeks through